Invasive lobular carcinoma is the second most common type of invasive breast cancer, yet it behaves so differently from the more familiar ductal type that it changes how surgeons and radiologists plan an operation. It rarely forms a firm lump, it is often invisible or underestimated on a mammogram, and its borders fade into healthy tissue rather than stopping at a clear edge. Those three properties make localization and complete resection harder than for most breast cancers. This article explains why lobular cancer is different at the cellular level, why that translates into a higher risk of positive margins, and where precise surgical marker navigation makes a measurable difference.
The defining feature of invasive lobular carcinoma is what the cancer cells fail to do. In most breast cancers the malignant cells stay connected to one another and grow as a cohesive mass that pushes against and distorts the surrounding tissue. In lobular cancer the cells lose the molecular bonds that normally hold breast cells together. Instead of clumping into a discrete tumor, they infiltrate the breast in thin single strands, weaving between normal structures without destroying them.
This single strand growth pattern is the root cause of almost every clinical challenge that follows. There is often no hard lump to feel, no dense mass to see, and no sharp boundary where tumor stops and normal tissue begins. For a general primer on tumor types, see What Is Breast Cancer.
Because lobular cells do not provoke the dense fibrous reaction that ductal tumors do, and because they rarely produce the microcalcifications that draw a radiologist's eye, lobular cancer is one of the most frequently mammographically occult breast cancers. It is detected later and at a larger size on average than ductal cancer, and even when it is found, its true extent is commonly underestimated by mammography and ultrasound.
This is why breast MRI plays a larger role in lobular cancer than in most other breast cancers. Literature indexed on PubMed consistently reports that MRI assesses lobular tumor extent more accurately than conventional imaging, which directly affects surgical planning. Dense breast tissue compounds the problem, as discussed in Breast Density and Its Impact on Tumor Localization and MRI Guided Localization in Breast Cancer Surgery.
Most localization techniques are built around a simple assumption: there is a target with a center, and the surgeon needs to find it. Lobular cancer breaks that assumption. The disease can extend well beyond what any single image suggests, it is more often multifocal, and the surgeon cannot rely on palpation to judge where the tumor ends during the operation.
In practice this means three things. First, a single marker placed at the center of the lesion may not represent the real surgical target. For larger or geographically spread lobular tumors, radiologists sometimes place more than one marker to define the boundaries of the area to be removed, a technique known as bracketing. Second, the surgeon operating on lobular cancer is navigating largely blind to tactile cues, which raises the value of any tool that reports distance to the target in real time. Third, intraoperative judgment about how much tissue to take is harder, because the usual feedback of feeling a firm edge is absent. For the foundations of localization, see Breast Cancer Localization.
The clinical consequence of indistinct borders is predictable. Lobular cancer is associated with higher rates of positive surgical margins and a greater likelihood of a second operation than ductal cancer of comparable size. A positive margin means cancer cells reach the edge of the removed tissue, which usually triggers a re excision to remove more.
This is exactly where localization quality stops being a convenience and becomes an oncologic factor. When the surgeon can navigate accurately to a stable marker and measure the distance between that marker and the cut surface during the operation, the resection can be planned around the actual target rather than around what can be felt. Published evidence on magnetic surgical marker navigation, including the first 200 case French series by Ceccato and colleagues in Scientific Reports (doi: 10.1038/s41598-025-88430-5), reported a 9 percent re excision rate against a wire guided benchmark of 14.9 to 20.8 percent. While that cohort was not lobular specific, the mechanism it demonstrates, reliable navigation to a defined target, is most valuable precisely in tumors like lobular cancer where the surgeon has the least tactile information to work with. A summary is available in the clinical one pager.
For a tumor the surgeon cannot feel and can barely see on imaging, the practical question during surgery is simple: how far am I from the target, and in which direction. The Pintuition System® answers that question continuously, providing real time distance and directional feedback to the Pintuition Marker® with millimeter level readout. In lobular surgery, where the edge is a matter of judgment rather than touch, that distance information substitutes for the tactile feedback the surgeon does not have.
One reported practical benefit is using the probe almost as an intraoperative ruler, checking the distance between the marker and the resection surface before the specimen is removed. For a diffuse tumor with no firm boundary, being able to verify that distance is a concrete advantage over relying on feel alone.
Sirius Medical developed Pintuition® as a Surgical Marker Navigation System for the excision of breast lesions that are difficult to localize, including the diffuse and often occult presentation of lobular cancer. The Pintuition Marker® is a non radioactive magnetic marker placed under standard image guidance, including the MRI and ultrasound guidance that lobular cases frequently require, and it can be placed well before the day of surgery.
During the operation, Pintuition® gives the surgeon continuous distance and directional guidance to the marker, with a signal that remains reliable in the presence of blood or fluid and is unaffected by electrocautery. For a wider view of how the technology fits into breast cancer care, see How Sirius Medical Oncology Medical Devices Support Breast Cancer Care.
Learn how Pintuition® can support precision and confidence in lobular cancer and other complex breast surgeries. Request a demo or explore the clinical overview for more information.
Disclaimer
This article is intended for informational purposes only and should not be considered medical advice. Clinical decisions should always be made by qualified healthcare professionals based on individual patient needs and current guidelines.